FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | Alzheimer's | amyloid beta

Alzheimer’s vax skirts deadly side effects

Scientific American is reporting on the successful advance of a preclinical Alzheimer's vaccine that combines small amounts of amyloid beta and interleukin-4, which is delivered in an inactivated herpes virus. In mice, the vaccine cleared amyloid beta. And researchers at Harvard say that because of the interleukin-4 the mice did not experience swelling--a dangerous side effect that thwarted earlier attempts to develop a similar vaccine.

"The problem with the previous trial of Aß vaccine was it led to a toxic response caused by activation of an inappropriate immune response," says Harvard's Michael Wolfe. "But this new vaccine sounds promising. I am most optimistic about this approach among all the things currently in trials right now." But he also acknowledges that we won't understand the long-term safety issues until large human trials are launched, which he hopes to see in three years.

- read the article in Scientific American

Related Articles:
Alzheimer's vaccine spurs immune response in mice
Scientists report Alzheimer's vaccine success
Alzheimer's patch used to deliver vaccine to mice


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Vaccine   Alzheimer's   amyloid beta  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.